Study: Popular GLP-1 Drug May Slow Down Biological Aging
A study from UC San Diego suggests that the GLP-1 drug semaglutide may slow biological aging by reducing inflammation and metabolic stress. Researchers observed these effects in patients with HIV-associated lipohypertrophy using epigenetic clocks to track cellular changes.
Why it matters
This research suggests potential secondary health benefits of weight-loss drugs, which could have significant implications for treating age-related diseases.
By calming inflammation and reducing excess fat, semaglutide may postpone several molecular signs of aging, pointing to the potential of GLP‑1 receptor agonists to help prevent age‑related diseases.
The article summarizes scientific findings from a university study without taking a stance on the drug's overall safety or efficacy.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in